Avacta Group plc (AIM: AVCT), the London-headquartered precision oncology developer with operations in Philadelphia, has reported preliminary human evidence that its experimental cancer treatment AVA6103 is releasing chemotherapy in a manner consistent with the company’s preclinical predictions. The findings, announced on September 16, 2026, cover 19 patients enrolled across the first three dose levels of the Phase 1 FOCUS-01 study. While the results support further investigation of Avacta’s controlled-release technology, they do not yet establish that the treatment delivers superior drug concentrations within tumours or produces clinically meaningful cancer responses.
The distinction is central to assessing the company’s progress. AVA6103 uses Avacta’s second-generation pre|CISION platform to deliver exatecan, a potent topoisomerase I inhibitor, through an enzyme-activated peptide-drug conjugate. The technology is designed to release the chemotherapy payload preferentially in the tumour microenvironment, potentially allowing more effective drug exposure while limiting damage to healthy tissues.
Initial safety observations and pharmacokinetic measurements suggest that important elements of this delivery approach are functioning as intended. However, Avacta’s proposed mechanism of sustained drug retention within tumours remains an interpretation of the circulating drug-related measurements rather than a finding directly confirmed by tumour biopsies. The company expects to present initial efficacy results and biopsy evidence during the first half of 2027, making that period a more consequential test of its scientific and commercial proposition.
The clinical milestone also coincides with a tighter financial timetable. On October 6, Avacta announced a conditional £12.5 million gross equity financing intended to extend its cash runway into the second quarter of 2027. The funding strengthens its ability to advance development, but the available runway and the expected efficacy-readout window do not perfectly overlap, leaving execution timing and future financing important considerations.
What has Avacta demonstrated in the first 19 patients treated with AVA6103?
The FOCUS-01 trial is a first-in-human, open-label Phase 1 study examining the safety, tolerability, pharmacokinetics and initial therapeutic activity of AVA6103 in selected advanced solid tumours. The trial began treating patients in March 2026 after the United States Food and Drug Administration cleared the investigational new drug application in January. Its dose-escalation stage investigates two treatment schedules, with administration every two weeks or every three weeks.
Avacta reported data from the first three dose levels, corresponding to exatecan payload doses of 1.5, 3.0 and 4.5 milligrams per square metre. Nineteen patients had been enrolled across those early cohorts, providing an initial basis for examining adverse events and the concentrations of the intact conjugate and released products in blood plasma.
The company reported that pharmacokinetic observations broadly followed predictions developed from preclinical experiments. In particular, plasma concentrations of intact AVA6103 declined relatively quickly after administration, while low concentrations of released exatecan and the accompanying peptide cleavage product remained detectable over a more prolonged period.
Avacta describes these results as clinical proof of mechanism because they are consistent with its intended controlled-release design. This is a meaningful step beyond demonstrating the technology in laboratory experiments or animal models, although the findings remain preliminary and company-reported.
The results do not establish a recommended Phase 2 dose, a maximum tolerated dose for AVA6103 or a validated relationship between drug exposure and tumour response. The study is continuing dose escalation, with the fourth dose level progressing in both treatment schedules. Consequently, the current evidence supports continued development rather than a definitive assessment of clinical benefit.
Why does the 48-hour pharmacokinetic finding matter for Avacta’s drug-reservoir hypothesis?
The strongest mechanistic argument in Avacta’s September announcement concerns how long the released peptide remains detectable after administration. The company reported low concentrations of the peptide cleavage product in plasma up to 48 hours after dosing, despite earlier work in its AVA6000 programme indicating that the released peptide has an independent circulating half-life of approximately two to three hours.
That observation is consistent with a continuing source of newly released material rather than a simple, rapid elimination pattern following a single release event. Avacta interprets the result as supporting its hypothesis that intact peptide-drug conjugate becomes retained in a tumour-associated reservoir and is gradually cleaved, releasing exatecan over an extended period.
If the interpretation is confirmed, it could have important consequences for cancer drug delivery. Sustained release inside the tumour microenvironment might prolong exposure to active chemotherapy while reducing the need for high circulating concentrations. This could potentially improve the relationship between antitumour activity and systemic toxicity.
However, plasma measurements alone cannot establish precisely where the cleavage reaction occurred. Circulating concentrations reflect several processes, including tissue distribution, binding, metabolism, cleavage and elimination. The reported alignment with preclinical modelling strengthens the mechanistic argument, but does not remove the need for direct human tumour measurements.
The distinction is particularly important because fibroblast activation protein, the enzyme targeted by the pre|CISION platform, is not absolutely exclusive to malignant tissue. Although it is commonly associated with cancer-related fibroblasts, FAP expression can also occur during wound healing and fibrosis. Tumour selectivity therefore depends on the biological distribution and activity of the target, not simply the presence of a theoretically tumour-associated enzyme.
The planned tumour-biopsy analysis must help establish whether AVA6103 is retained and cleaved within human tumours in a manner consistent with the company’s model. Demonstrating prolonged drug release is important, but proving that the release occurs preferentially at the intended site is a separate scientific hurdle.
Does AVA6103’s early tolerability mean it is safer than conventional exatecan?
Avacta’s initial safety findings are encouraging, but they require more careful interpretation than a direct comparison of adverse-event percentages might suggest. Among the 19 patients evaluated across the first three dose levels, the company reported no neutropenia, thrombocytopenia in one patient, anaemia in three patients, and nausea or vomiting in one patient. These results provide a preliminary indication of tolerability in the population and exposure range studied.
The company compared those observations with historical Phase 1 studies of conventional exatecan and trastuzumab deruxtecan, the antibody-drug conjugate marketed as Enhertu. Avacta highlighted that the highest AVA6103 dose tested contained approximately 50% more nominal exatecan payload per square metre than the maximum tolerated dose established for conventional exatecan under a historical treatment regimen.
However, the original conventional exatecan study used administration on five consecutive days, while AVA6103 is being administered every two or three weeks. The treatments also differ in molecular formulation, delivery mechanism and the distribution of active drug exposure. Consequently, comparing the nominal payload doses does not establish an equivalent difference in systemic exposure or prove that AVA6103 has a wider therapeutic window.
The comparison with Enhertu introduces additional limitations. Trastuzumab deruxtecan is an antibody-drug conjugate carrying a related topoisomerase I inhibitor payload, but it is not identical to AVA6103. The historical studies also involved different patient populations, treatment schedules and clinical circumstances, making direct comparison of adverse-event rates potentially misleading.
The absence of neutropenia among 19 patients is encouraging, particularly for a cytotoxic treatment, but the sample is too small to exclude clinically important toxicity at higher doses or with longer exposure. Adverse events may also become more apparent with repeated treatment cycles or in different patient populations.
A genuine improvement in the therapeutic window would require evidence that clinically useful antitumour activity can be achieved at doses patients can tolerate. That balance has not yet been established for AVA6103, meaning its initial safety findings support further investigation rather than a demonstrated safety advantage over approved therapies.
What does the preclinical comparison with Enhertu really establish?
Avacta’s September announcement also highlighted an experiment comparing AVA6103 with Enhertu in a patient-derived gastric cancer xenograft model expressing HER2 and FAP. The company reported deep and prolonged partial responses in all six animals treated with AVA6103, while Enhertu slowed tumour growth and produced smaller reductions in a subset of animals.
The findings suggest that AVA6103 can generate substantial antitumour activity under the conditions used in that model. They also provide a rationale for exploring whether enzyme-activated drug delivery could offer advantages in some biological settings where conventional antibody-drug conjugates may face limitations.
However, the comparison was conducted in mice rather than patients, and the groups were small. AVA6103 was administered using a repeated, dose-dense schedule, while Enhertu was given according to a different experimental regimen. Differences in treatment frequency and cumulative exposure could influence the results independently of the molecular delivery mechanism.
The experiment therefore cannot establish that AVA6103 is clinically superior to Enhertu. Nor can it determine how the two medicines would compare across human tumour types with different levels of HER2 expression, FAP activity or treatment resistance.
The stronger interpretation is that Avacta has generated preclinical evidence supporting further clinical testing of AVA6103. Meaningful competitive claims will require human efficacy and safety data, along with an understanding of which patient populations could benefit from the different treatment approaches.
What would the 2027 tumour biopsies and efficacy results need to prove?
The planned first-half 2027 readout is important because it could begin connecting Avacta’s pharmacokinetic findings with direct evidence from human tumours and measurable treatment activity. The upcoming results are expected to include clinical tumour-biopsy observations intended to test the proposed drug-reservoir mechanism. They may also provide initial information about objective tumour responses at the doses evaluated.
Tumour-biopsy evidence could strengthen the scientific argument if it demonstrates the presence and persistence of relevant drug components within tumour tissue. The interpretation would be more informative if measurements distinguish intact AVA6103 from released exatecan and can be related to circulating concentrations. However, the available disclosures do not establish that every such measurement will necessarily be included in the first data presentation.
Clinical efficacy represents a separate requirement. FOCUS-01 includes objective response rate, duration of response, progression-free survival and overall survival among its secondary outcome measures. Objective responses assessed under RECIST 1.1 criteria would provide a more direct indication of antitumour activity than pharmacokinetic measurements alone.
The trial’s primary endpoints concern safety, adverse events and dose-limiting toxicities, consistent with its early development stage. Consequently, initial efficacy results may involve limited patient numbers, incomplete follow-up and several different cancer indications. Such findings could support dose selection and subsequent trial design without providing the evidence required for regulatory approval.
The distinction between drug retention and clinical response is essential. A treatment could demonstrate substantial tumour-associated drug exposure without producing meaningful tumour shrinkage if the cancer is resistant to its payload or if the drug fails to reach relevant tumour cells. Conversely, early responses could emerge before the full mechanism has been characterised.
The strongest outcome would combine supportive tumour-biopsy findings, sustained tolerability and objective responses that can be interpreted alongside dose and exposure. That combination would address multiple uncertainties simultaneously, although it would still require confirmation in larger and more appropriately designed clinical studies.
An unfavourable or mixed outcome would also require careful interpretation. Failure to demonstrate substantial tumour responses at early dose levels would not automatically disprove the delivery technology, particularly if higher doses remain under investigation. However, repeated failure to translate mechanistic evidence into useful clinical activity would weaken the commercial argument for further development.
Why could the two dosing schedules and different cancer types complicate the initial efficacy data?
FOCUS-01 is examining AVA6103 using both two-week and three-week dosing schedules, potentially allowing the company to investigate whether more frequent administration improves treatment exposure without unacceptable toxicity. This flexibility is important because sustained drug release could create opportunities to adjust dose intensity differently from conventional chemotherapy or antibody-drug conjugates. However, the optimal schedule remains an experimental question rather than an established advantage.
The study also includes patients with several advanced solid tumours, including pancreatic, colorectal, gastric or gastroesophageal junction, cervical and small-cell lung cancers. These diseases differ in biological characteristics, prior treatment patterns and potential sensitivity to topoisomerase I inhibition. As a result, responses observed across a small, heterogeneous early-stage population may be difficult to interpret as evidence of activity in any one indication.
The relationship between FAP expression and treatment activity may also vary. The presence of cancer-associated fibroblasts and the spatial distribution of FAP within tumours could influence drug cleavage, while differences in blood supply and tissue architecture may affect delivery. Evidence from one cancer type cannot therefore be assumed to apply uniformly across the broader development programme.
Avacta’s September presentation on pancreatic cancer added preclinical support for using AVA6103 in that disease, including observations involving FAP-expressing fibroblasts near tumour cells and blood vessels. Those results strengthen the rationale for investigating the indication, but they do not establish human pancreatic cancer efficacy.
The eventual development strategy will depend on identifying doses, treatment schedules and cancer populations in which the balance between response and tolerability appears most favourable. Patient selection and indication prioritisation could become as important to commercial success as the underlying controlled-release technology.
Does Avacta’s earlier AVA6000 clinical progress validate AVA6103?
Avacta’s first-generation programme, AVA6000, provides relevant context because it also uses the pre|CISION platform to deliver chemotherapy through an FAP-activated mechanism. The company has reported encouraging clinical activity in selected salivary gland cancer patients and has discussed further development requirements with the United States Food and Drug Administration. These findings provide human evidence supporting the broader platform concept.
However, AVA6000 and AVA6103 are different investigational medicines. AVA6000 delivers doxorubicin through a first-generation construct, while AVA6103 delivers exatecan through a second-generation design intended to support prolonged release. Their molecular properties, payload toxicities and treatment regimens therefore differ.
The AVA6000 experience may reduce uncertainty about the general feasibility of FAP-enabled drug delivery, but it cannot establish the safety or efficacy of AVA6103. The second-generation sustained-release mechanism introduces additional questions that must be addressed through its own clinical programme.
This distinction is particularly important for commercial interpretation. Success with one platform candidate can increase confidence in the underlying technology, but regulatory authorities and potential licensing partners must evaluate the evidence supporting each asset independently. The value of AVA6103 will ultimately depend on its own clinical findings rather than the assumption that progress elsewhere in Avacta’s pipeline guarantees comparable outcomes.
Can Avacta’s new £12.5 million financing support the anticipated clinical readout?
Avacta’s financial position provides an important constraint on its development strategy. The company’s September 30 interim results disclosed £20.27 million in cash and short-term deposits at June 30, compared with £10.59 million in cash at August 31. The figures demonstrate a substantial reduction in reported liquidity over the two-month period, although they should not be used alone to calculate a sustainable monthly cash-burn rate because the disclosed balances and classifications may not be directly comparable.
On October 6, Avacta announced that it had conditionally secured £12.5 million in gross proceeds through a placing and subscription priced at 68 pence per share. The transaction involves 17,411,766 placing shares and 970,587 subscription shares, bringing the total proposed issuance to 18,382,353 ordinary shares. These represent approximately 3.9% of the company’s existing issued share capital, with admission of the new shares expected on October 9, subject to the transaction conditions.
The financing is expected to extend the company’s cash runway into the second quarter of 2027. Management has indicated that the additional resources should support several development milestones, including the anticipated initial AVA6103 efficacy data. Nevertheless, the difference between an expected runway extending into Q2 and a clinical readout scheduled broadly for the first half of 2027 remains financially important.
If the clinical programme progresses according to schedule, the financing could allow Avacta to present additional evidence before another substantial funding decision becomes necessary. Delays in patient recruitment, treatment, follow-up or data analysis could narrow that flexibility, particularly if expenditure remains elevated.
The timing of potential partnering agreements introduces another uncertainty. A successful licensing transaction might provide upfront funding or shared development resources, but ongoing discussions do not establish that a deal will be completed. No hypothetical partnership payment should therefore be included as available liquidity before a binding transaction is announced.
The latest financing improves the immediate funding position but does not remove the possibility of further capital requirements. Advancing AVA6103 through subsequent clinical studies, alongside other development programmes, may demand resources beyond those currently available. The clinical evidence generated during the next development period will consequently influence both the company’s commercial position and its future financing alternatives.
How have Avacta shares responded to the financing and clinical developments?
Avacta shares closed at 63.5 pence on October 7, 2026, compared with 72 pence on September 29, the last trading session before the company’s capital access window. The decline occurred around the latest financing process, although short-term share-price movements cannot be attributed conclusively to a single announcement. Existing shares resumed trading on October 6 following the closure of the capital access window.
The new shares were priced at 68 pence, representing a 5.6% discount to the September 29 closing mid-market price. While the discount was relatively modest against that reference price, the subsequent trading performance demonstrates that financing terms and longer-term valuation expectations are separate considerations.
Avacta’s market position reflects competing developments. Initial human pharmacokinetic findings support further investigation of its controlled-release platform, while the company remains dependent on clinical trials to demonstrate whether that technology produces commercially meaningful treatment outcomes. The additional equity financing also provides resources for development while increasing the number of shares over which any future corporate value would be distributed.
The next clinical readout could influence perceptions of the programme, but its financial significance will depend on the strength and completeness of the evidence. Early efficacy signals, if reported, must be interpreted in the context of patient numbers, dose levels, cancer indications and follow-up duration.
A more durable reassessment of Avacta’s commercial prospects would require evidence that its technology provides a useful therapeutic advantage and that the company has a credible development and financing route towards larger studies.
What would make AVA6103 attractive to a pharmaceutical development partner?
For Avacta, the commercial significance of the next data package extends beyond establishing whether AVA6103 merits continued development. The company is also seeking to demonstrate that its broader controlled-release technology could support additional cancer treatments and potentially generate value through partnerships.
Avacta has indicated that discussions with potential partners are continuing. Preliminary clinical evidence consistent with the intended release mechanism may strengthen those discussions because it addresses an important uncertainty about whether the technology behaves as expected in humans. However, pharmaceutical companies considering licensing arrangements would still need to assess the quality of the efficacy evidence, safety profile, manufacturing requirements, intellectual-property position and commercial opportunity.
The next results could help determine whether AVA6103 offers an identifiable therapeutic advantage within a particular patient population. Objective tumour responses accompanied by manageable toxicity and supportive biopsy findings would provide a stronger basis for evaluating that opportunity than pharmacokinetic evidence alone.
A partnership could involve upfront payments, development milestones, royalties or shared clinical expenditure, depending on the eventual agreement. None of those potential financial benefits can be assumed before terms are negotiated and a binding transaction is completed.
The broader platform opportunity is also conditional. Avacta’s second-generation technology may be adaptable to different chemotherapy payloads, while its AVA6207 programme is exploring a dual-payload approach. However, individual development candidates will still require their own safety, pharmacology and efficacy evidence.
Avacta has crossed an important early clinical threshold by reporting human pharmacokinetic behaviour consistent with the proposed controlled-release mechanism of AVA6103. The results support the scientific rationale for continued development, but do not yet prove preferential drug accumulation in human tumours or demonstrate clinically meaningful treatment benefit.
The anticipated first-half 2027 data could begin addressing both uncertainties through tumour-biopsy measurements and initial efficacy observations. The company’s latest financing provides additional resources to pursue those milestones, while its future financial position will remain sensitive to clinical timing, expenditure and the possibility of commercial partnerships.
The decisive test for Avacta is therefore not simply whether AVA6103 can release exatecan over an extended period. It is whether that release produces sufficient drug exposure inside tumours to generate meaningful cancer responses without unacceptable toxicity. Establishing that connection would provide a materially stronger foundation for further clinical development and commercial negotiations than the preliminary proof-of-mechanism findings alone.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
